Pharmaceuticals
Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC
* China NMPA cleared the IND application of BBT-401 submitted on September 25, 2019 * The Phase I clinical study in China will be initiated in May 2020 SEONGNAM, South Korea, Dec. 26, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc. (KOSDAQ: 288330), a clinical stage biotech company headquart...
2019-12-27 06:30
1691
Viva Biotech Awarded 'Top 10 Public Companies'
BEIJING, Dec. 24, 2019 /PRNewswire/ -- The 'Future Healthcare VB 100 Summit' organized by VCBeat and VCBeat Research was held inBeijing. Viva Biotech was invited to the Summit and awarded the 'Top 10 Public Companies 2019' with honor. Dr. David Xu, the Chief Business Officer of Viva Biotech, was ...
2019-12-24 18:18
1439
Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC
SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the Ministry...
2019-12-20 10:19
1240
Specialised Therapeutics Signs Exclusive Deal for New Haematology Drug
SINGAPORE, Dec. 18, 2019 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed an exclusive license deal with US-based Onconova Therapeutics (NASDAQ: ONTX), securing commercialisation rights to a new therapy for the treatment of Myelodysplastic Syndrome...
2019-12-18 22:00
2729
Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry
SHANGHAI, Dec. 17, 2019 /PRNewswire/ -- Shanghai ChemPartner announced the appointment ofJie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters inShanghai, China. Dr. Li is an established chemist with over 20 years of experience in both medicinal chemistry and ...
2019-12-18 00:00
1919
iX Biopharma Reports on Outcome of Wafermine End-of-phase 2 Meeting with US FDA
SINGAPORE, Dec. 11, 2019 /PRNewswire/ -- Specialty pharmaceutical company iX Biopharma Ltd(SGX:42C) ("iX Biopharma" or, "the Company") is pleased to announce that it has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Wafermine, a sublin...
2019-12-11 22:00
1896
Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies
SUZHOU, China and SHANGHAI, Dec. 9, 2019 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd ("Gracell"), a clinical-stage immune cell therapy company, today announced the progressive clinical outcomes for leading product candidates FasTCAR-19, Dual CAR-19-22, and Dual CAR-BCMA-19 at the American...
2019-12-09 22:00
1345
Hebron Announces $6.5 Million Private Placement
WENZHOU, China, Dec. 9, 2019 /PRNewswire/ -- Hebron Technology Co., Ltd. (" Hebron" or the "Company") (Nasdaq: HEBT), a developer, manufacturer and installer of valves and pipe fittings for use in the pharmaceutical, biological, food and beverage, and other clean industries, today announced that ...
2019-12-09 21:30
2213
BJ Bioscience Announces First Patient Dosed in FIH Trial of BJ-001 in Patients with Locally Advanced/Metastatic Solid Tumors
HANGZHOU, China, Dec. 9, 2019 /PRNewswire/ -- BJ Bioscience Inc. (the
'company') today announced that the first patient was successfully dosed on
December 4, 2019 in the first-in-human (FIH) trial of the company's BJ-001
program at NEXT ONCOLOGY inSan Antonio, Texas.
2019-12-09 21:00
1395
Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection - Lumosa to Initiate the Bridging Study in the US
TAIPEI, Dec. 3, 2019 /PRNewswire/ -- Opioid misuse, addiction, and overdoses have caused significant social and economic burdens leading to the opioid crisis. LT1001 (brand name Naldebain®) is a prodrug of nalbuphine, an abuse-free analgesic that has been marketed worldwide for decades. Naldebain...
2019-12-03 17:36
1068
New Early Breast Cancer Drug Approved by Singapore Health Sciences Authority
* NERLYNX® (neratinib) now approved in Singapore for HER2+ breast cancer patients following adjuvant trastuzumab-based therapy * NERLYNX is the first therapy in the Specialised Therapeutics' portfolio approved inSE Asia * Five-year follow up data show NERLYNX reduces risk of invasive disease...
2019-12-03 05:30
1168
Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly
SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics (01801.HK), a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Tyvyt® (generic name: sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal anti...
2019-12-02 09:37
5233
Ascentage Pharma Breaks Ground on its Global Headquarters, R&D Center and Manufacturing Facility in the Suzhou Industrial Park
SUZHOU, China and ROCKVILLE, Md., Nov. 20, 2019 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies, announced that the groundbreaking ceremony for the Company's global headquarters, R&D center, and manufacturi...
2019-11-21 11:30
1650
3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration
SHENYANG, China and BEDFORD Mass., Nov. 17, 2019 /PRNewswire/ -- 3SBio Inc.
2019-11-18 08:30
4088
Viva Biotech Partnership Summit Successfully Launched in Shanghai
SHANGHAI, Nov. 15, 2019 /PRNewswire/ -- 2019 Viva Biotech Partnership Summit (the "Summit") was successfully launched on8 November 2019 in Pudong, Shanghai, themed "Innovation Partnership Growth". Founders from over 30 global innovative and biopharmaceutical companies incubated/ invested by Viva ...
2019-11-15 14:16
2264
I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China
SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced that Natio...
2019-11-14 23:45
1107
Samsung Biologics Enhances Its Trusted Service as the First and Only ISO27001 Certified CDMO
INCHEON, South Korea, Nov. 14, 2019 /PRNewswire/ -- Samsung Biologics announced that it has obtained ISO 27001 certification, the most prestigious international standard on information security management. Samsung Biologics is the first CDMO company to be ISO 27001 certified globally. A ceremony...
2019-11-14 20:00
1366
China Biologic Reports Financial Results for the Third Quarter of 2019
BEIJING, Nov. 13, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the third quarter of 2019. Third Quarter...
2019-11-14 05:43
6376
Akesobio Presents Phase 1 Clinical Data from First-in-class Bispecific Drug Candidate AK104 (PD1/CTLA4) As Oral Presentation, at 2019 SITC Annual Meeting
NATIONAL HARBOR, Md., Nov. 11, 2019 /PRNewswire/ -- Akeso Biopharma ("Akeso") presented results of phase 1 study of its first-in-class bispecific drug candidate AK104, in patients with advanced solid tumors in 2019 Society for Immunotherapy of Cancer ("SITC"). AK104 is a novel, tetrameric bispec...
2019-11-11 17:35
2290
Enzene Opens its First Continuous Biologics Manufacturing Facility With a Promise to Disrupt the mAb Manufacturing Cost
PUNE, India, Nov. 7, 2019 /PRNewswire/ -- Enzene Biosciences today formally opened its first fully connected continuous Biologics manufacturing facility in Pune, India. This first-of-its-kind facility was built in half the time as compared to the conventional biologics manufacturing plants. The s...
2019-11-07 20:24
1533
Week's Top Stories
Most Reposted
Agoda Partners with Sands China to Boost Tourism
[Picked up by 316 media titles]
2024-09-05 11:00The Beach Grill Unveils Exciting New Dishes: Elevating The Beachfront Dining Experience
[Picked up by 297 media titles]
2024-09-05 11:21
povo2.0, Japan's favourite digital telco, achieves highest user engagement and customer satisfaction rates with Circles' SaaS technology
[Picked up by 294 media titles]
2024-09-06 10:00Armacell will take complete ownership of the successful aerogel joint venture, AJA, following an agreement with JIOS Aerogel
[Picked up by 285 media titles]
2024-09-02 14:00Shiperoo Pioneers Tech-led Retail Returns and Fulfilment with AUD 30 Million Investment in Robotic Automated Facilities in Australia and New Zealand
[Picked up by 276 media titles]
2024-09-04 09:12
Most Read
Shiperoo Pioneers Tech-led Retail Returns and Fulfilment with AUD 30 Million Investment in Robotic Automated Facilities in Australia and New Zealand
2024-09-04 09:12
7610
Agoda Partners with Sands China to Boost Tourism
2024-09-05 11:00
6941
The Beach Grill Unveils Exciting New Dishes: Elevating The Beachfront Dining Experience
2024-09-05 11:21
5381
Yadea Enters Thai Market with Grand Opening of Three New Stores
2024-09-01 12:44
4394
